The overall goal of the Alzheimer's Disease Research Center (ADRC) at Johns Hopkins University (JHU) is to facilitate research in Alzheimer's disease (AD) and related disorders throughout the research community at JHU and associated institutions. The ADRC is comprised of four Cores: a Clinical Core , a Data Management and Statistics Core, a Neuropathology Core, and an Education Core. The cores will work together to provide the infrastructure and resources to the JHU community so that clinical and basic research in AD and related disorders can continue to flourish and expand. In addition, three projects are proposed. The first Project pertains to executive function impairments in subjects with Mild Cognitive Impairment (MCI) and their relation to progression of cognitive decline over time. The second Project pertains to the clinical-pathological-biochemical alterations present in the earliest stage of pathology in the perforant pathway of the medial temporal lobe among individuals who have come to autopsy, and are either normal, meet criteria for MCI, or have mild AD. The third Project will examine neuropathological, neurochemical, and biochemical aspects of synaptic pathology occurring in several lines of behaviorally-characterized transgenic mice. Cooperative studies with investigators at other ADCs and related research institutions will continue to be conducted, including multi-center clinical trials. Data sharing with other investigators in the AD research community will continue through regular submissions to the National Alzheimer Disease Coordinating Center (NACC).

Agency
National Institute of Health (NIH)
Institute
National Institute on Aging (NIA)
Type
Specialized Center (P50)
Project #
5P50AG005146-24
Application #
7233206
Study Section
Special Emphasis Panel (ZAG1-ZIJ-7 (J4))
Program Officer
Phelps, Creighton H
Project Start
1997-07-15
Project End
2010-03-31
Budget Start
2007-04-15
Budget End
2008-03-31
Support Year
24
Fiscal Year
2007
Total Cost
$1,828,617
Indirect Cost
Name
Johns Hopkins University
Department
Pediatrics
Type
Schools of Medicine
DUNS #
001910777
City
Baltimore
State
MD
Country
United States
Zip Code
21218
Fredericks, Carolyn A; Sturm, Virginia E; Brown, Jesse A et al. (2018) Early affective changes and increased connectivity in preclinical Alzheimer's disease. Alzheimers Dement (Amst) 10:471-479
Seddighi, Sahba; Varma, Vijay R; An, Yang et al. (2018) SPARCL1 Accelerates Symptom Onset in Alzheimer's Disease and Influences Brain Structure and Function During Aging. J Alzheimers Dis 61:401-414
Alosco, Michael L; Sugarman, Michael A; Besser, Lilah M et al. (2018) A Clinicopathological Investigation of White Matter Hyperintensities and Alzheimer's Disease Neuropathology. J Alzheimers Dis 63:1347-1360
Holingue, Calliope; Wennberg, Alexandra; Berger, Slava et al. (2018) Disturbed sleep and diabetes: A potential nexus of dementia risk. Metabolism 84:85-93
Brent, Robert J (2018) Estimating the monetary benefits of medicare eligibility for reducing the symptoms of dementia. Appl Econ 50:6327-6340
van Bergen, Jiri M G; Li, Xu; Quevenco, Frances C et al. (2018) Low cortical iron and high entorhinal cortex volume promote cognitive functioning in the oldest-old. Neurobiol Aging 64:68-75
Deming, Yuetiva; Dumitrescu, Logan; Barnes, Lisa L et al. (2018) Sex-specific genetic predictors of Alzheimer's disease biomarkers. Acta Neuropathol 136:857-872
Kim, Sangjune; Yun, Seung Pil; Lee, Saebom et al. (2018) GBA1 deficiency negatively affects physiological ?-synuclein tetramers and related multimers. Proc Natl Acad Sci U S A 115:798-803
Hohman, Timothy J; Dumitrescu, Logan; Barnes, Lisa L et al. (2018) Sex-Specific Association of Apolipoprotein E With Cerebrospinal Fluid Levels of Tau. JAMA Neurol 75:989-998
Burke, Shanna L; Maramaldi, Peter; Cadet, Tamara et al. (2018) Decreasing hazards of Alzheimer's disease with the use of antidepressants: mitigating the risk of depression and apolipoprotein E. Int J Geriatr Psychiatry 33:200-211

Showing the most recent 10 out of 830 publications